Genenta Science (GNTA) Competitors

Genenta Science logo
$1.10 +0.11 (+11.01%)
Closing price 11/3/2026
Extended Trading
$1.10 0.00 (0.00%)
As of 11/3/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GNTA vs. NBP, AVXL, HURA, ANIX, and KZIA

Should you buy Genenta Science stock or one of its competitors? Genenta Science's main competitors and comparable companies include Novabridge Biosciences (NBP), Anavex Life Sciences (AVXL), TuHURA Biosciences (HURA), Anixa Biosciences (ANIX), and Novogen (KZIA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genenta Science compare to Novabridge Biosciences?

Novabridge Biosciences (NASDAQ:NBP) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novabridge BiosciencesN/AN/A-$46.27M-$0.36N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

Company Net Margins Return on Equity Return on Assets
Novabridge BiosciencesN/A N/A N/A
Genenta Science N/A N/A N/A

38.4% of Novabridge Biosciences shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 22.1% of Novabridge Biosciences shares are owned by insiders. Comparatively, 29.0% of Genenta Science shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Novabridge Biosciences has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

Novabridge Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 922.96%. Given Novabridge Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Novabridge Biosciences is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novabridge Biosciences
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Novabridge Biosciences had 1 more articles in the media than Genenta Science. MarketBeat recorded 1 mentions for Novabridge Biosciences and 0 mentions for Genenta Science. Novabridge Biosciences' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company Overall Sentiment
Novabridge Biosciences Neutral
Genenta Science Neutral

Summary

Novabridge Biosciences beats Genenta Science on 6 of the 8 factors compared between the two stocks.

How does Genenta Science compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and Genenta Science (NASDAQ:GNTA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 3,096.00%. Given Anavex Life Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Genenta Science's return on equity of 0.00% beat Anavex Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life SciencesN/A -11.43% -10.72%
Genenta Science N/A N/A N/A

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 15.1% of Genenta Science shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by company insiders. Comparatively, 29.0% of Genenta Science shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$46.38M-$0.15N/A
Genenta ScienceN/AN/A-$7.39MN/AN/A

In the previous week, Anavex Life Sciences had 12 more articles in the media than Genenta Science. MarketBeat recorded 12 mentions for Anavex Life Sciences and 0 mentions for Genenta Science. Anavex Life Sciences' average media sentiment score of 0.00 equaled Genenta Science'saverage media sentiment score.

Company Overall Sentiment
Anavex Life Sciences Neutral
Genenta Science Neutral

Anavex Life Sciences has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, Genenta Science has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Summary

Anavex Life Sciences beats Genenta Science on 6 of the 10 factors compared between the two stocks.

How does Genenta Science compare to TuHURA Biosciences?

Genenta Science (NASDAQ:GNTA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

Genenta Science has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, TuHURA Biosciences has a beta of -0.23, indicating that its share price is 123% less volatile than the broader market.

In the previous week, TuHURA Biosciences had 20 more articles in the media than Genenta Science. MarketBeat recorded 20 mentions for TuHURA Biosciences and 0 mentions for Genenta Science. TuHURA Biosciences' average media sentiment score of 0.75 beat Genenta Science's score of 0.00 indicating that TuHURA Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Genenta Science Neutral
TuHURA Biosciences Positive

TuHURA Biosciences has a consensus target price of $9.50, indicating a potential upside of 598.53%. Given TuHURA Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe TuHURA Biosciences is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
TuHURA Biosciences
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by company insiders. Comparatively, 6.1% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Genenta Science's return on equity of 0.00% beat TuHURA Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
TuHURA Biosciences N/A -148.80%-95.74%

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
TuHURA BiosciencesN/AN/A-$30.05M-$0.50N/A

Summary

Genenta Science beats TuHURA Biosciences on 6 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Anixa Biosciences?

Genenta Science (NASDAQ:GNTA) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
Anixa BiosciencesN/AN/A-$10.93M-$0.32N/A

Genenta Science's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
Anixa Biosciences N/A -76.59%-67.80%

Anixa Biosciences has a consensus target price of $8.00, suggesting a potential upside of 207.69%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Anixa Biosciences is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anixa Biosciences
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Anixa Biosciences had 4 more articles in the media than Genenta Science. MarketBeat recorded 4 mentions for Anixa Biosciences and 0 mentions for Genenta Science. Genenta Science's average media sentiment score of 0.00 beat Anixa Biosciences' score of -0.39 indicating that Genenta Science is being referred to more favorably in the media.

Company Overall Sentiment
Genenta Science Neutral
Anixa Biosciences Neutral

Genenta Science has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

Summary

Genenta Science beats Anixa Biosciences on 6 of the 11 factors compared between the two stocks.

How does Genenta Science compare to Novogen?

Genenta Science (NASDAQ:GNTA) and Novogen (NASDAQ:KZIA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, earnings, profitability, institutional ownership, valuation, media sentiment and analyst recommendations.

Novogen has a consensus price target of $29.50, suggesting a potential upside of 451.40%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Genenta Science.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genenta Science
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Novogen
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78

Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Novogen has a beta of 2.34, suggesting that its stock price is 134% more volatile than the broader market.

15.1% of Genenta Science shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 29.0% of Genenta Science shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genenta Science has higher earnings, but lower revenue than Novogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genenta ScienceN/AN/A-$7.39MN/AN/A
Novogen$1.29M53.79-$13.41MN/AN/A

Company Net Margins Return on Equity Return on Assets
Genenta ScienceN/A N/A N/A
Novogen N/A N/A N/A

In the previous week, Novogen had 3 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Novogen and 0 mentions for Genenta Science. Novogen's average media sentiment score of 0.20 beat Genenta Science's score of 0.00 indicating that Novogen is being referred to more favorably in the news media.

Company Overall Sentiment
Genenta Science Neutral
Novogen Neutral

Summary

Novogen beats Genenta Science on 8 of the 10 factors compared between the two stocks.

Get Genenta Science News Delivered to You Automatically

Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GNTA vs. The Competition

MetricGenenta ScienceBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$25.93M$3.95B$7.47B$11.44B
Dividend YieldN/A3.63%2.47%4.64%
P/E RatioN/A23.7632.8129.51
Price / SalesN/A15.197.995.27
Price / CashN/A22.7220.8521.62
Price / Book0.854.174.383.65
Net Income-$7.39M-$23.99M$3.51B$394.00M
7 Day PerformanceN/A-7.12%-6.17%-6.39%
1 Month Performance66.82%-9.02%-7.05%-8.76%
1 Year Performance-37.91%-6.68%-2.50%-8.47%

Genenta Science Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GNTA
Genenta Science
0.8324 of 5 stars
$1.10
+11.0%
N/A-44.8%$25.93MN/AN/A9
NBP
Novabridge Biosciences
1.8914 of 5 stars
$0.86
+0.1%
$9.00
+945.3%
N/A$99.88M$3.89MN/A30
AVXL
Anavex Life Sciences
1.6466 of 5 stars
$1.06
-6.2%
$21.33
+1,912.6%
-79.4%$98.26MN/AN/A34
HURA
TuHURA Biosciences
1.8341 of 5 stars
$1.52
+0.7%
$9.00
+492.1%
-29.0%$96.87MN/AN/A22
ANIX
Anixa Biosciences
2.9836 of 5 stars
$2.78
-9.2%
$8.00
+187.8%
-33.9%$96.63MN/AN/A4

Related Companies and Tools


This page (NASDAQ:GNTA) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners